{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:13:44Z","timestamp":1790064824863,"version":"4.0.1"},"reference-count":150,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T00:00:00Z","timestamp":1551571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The emergence and spread of antibiotic-resistant pathogens is a major public health issue, which requires global action of an intersectoral nature. Multidrug-resistant (MDR) pathogens\u2014especially \u201cESKAPE\u201d bacteria\u2014can withstand lethal doses of antibiotics with various chemical structures and mechanisms of action. Pharmaceutical companies are increasingly turning away from participating in the development of new antibiotics, due to the regulatory environment and the financial risks. There is an urgent need for innovation in antibiotic research, as classical discovery platforms (e.g., mining soil Streptomycetes) are no longer viable options. In addition to discovery platforms, a concept of an ideal antibiotic should be postulated, to act as a blueprint for future drugs, and to aid researchers, pharmaceutical companies, and relevant stakeholders in selecting lead compounds. Based on 150 references, the aim of this review is to summarize current advances regarding the challenges of antibiotic drug discovery and the specific attributes of an ideal antibacterial drug (a prodrug or generally reactive compound with no specific target, broad-spectrum antibacterial activity, adequate penetration through the Gram-negative cell wall, activity in biofilms and in hard-to-treat infections, accumulation in macrophages, availability for oral administration, and for use in sensitive patient groups).<\/jats:p>","DOI":"10.3390\/molecules24050892","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T05:45:36Z","timestamp":1551678336000},"page":"892","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":224,"title":["The Concept of an Ideal Antibiotic: Implications for Drug Design"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-0365","authenticated-orcid":false,"given":"M\u00e1ri\u00f3","family":"Gajd\u00e1cs","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3201\/eid2305.161556","article-title":"The Discovery of Penicillin\u2014New Insights after More Than 75 Years of Clinical Use","volume":"23","author":"Gaynes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jac\/dks199","article-title":"Education of healthcare professionals and the public","volume":"67","author":"McNulty","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/ijerph10094274","article-title":"Strategies to Minimize Antibiotic Resistance","volume":"10","author":"Lee","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmi.2017.08.026","article-title":"What is antimicrobial stewardship?","volume":"23","author":"Dyar","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","first-page":"249","article-title":"[The opinions of community pharmacists related to antibiotic use and resistance] (article in Hungarian)","volume":"88","author":"Paulik","year":"2018","journal-title":"Acta Pharm. Hung."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20140082","DOI":"10.1098\/rstb.2014.0082","article-title":"Tackling the threat of antimicrobial resistance: From policy to sustainable action","volume":"370","author":"Shallcross","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"FSO290","DOI":"10.4155\/fsoa-2017-0109","article-title":"Antimicrobial resistance mechanisms and potential synthetic treatments","volume":"4","author":"Ali","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Munita, J.M., and Arias, C.A. (2016). Mechanisms of Antibiotic Resistance. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/MMBR.00039-14","article-title":"Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens","volume":"79","author":"Chang","year":"2015","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.biochem.78.082907.145923","article-title":"Multidrug resistance in bacteria","volume":"78","author":"Nikaido","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","article-title":"EUCAST expert rules in antimicrobial susceptibility testing","volume":"19","author":"Leclercq","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","unstructured":"O\u2019Neill, J. (2019, January 23). Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Available online: https:\/\/amr-review.org\/sites\/default\/files\/AMRReviewPaper-Tacklingacrisisforthehealthandwealthofnations_1.pdf."},{"key":"ref_15","unstructured":"World Health Organisation (2019, January 23). Antimicrobial Resistance: Global Report on Surveillance. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/112642\/1\/9789241564748_eng.pdf?ua=1."},{"key":"ref_16","unstructured":"(2019, January 23). ECDC\/EMEA Joint Technical Report (2009). The Bacterial Challenge: Time to React. Available online: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf."},{"key":"ref_17","unstructured":"(2019, January 23). CDC Antibiotic\/Antimicrobial Resistance (AR\/AMR), Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest_threats.html."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2475067","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1099\/mic.0.078295-0","article-title":"Eliciting antibiotics active against the ESKAPE pathogens in a collection of actinomycetes isolated from mountain soils","volume":"160","author":"Zhu","year":"2014","journal-title":"Microbiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1128\/JCM.02250-16","article-title":"Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing","volume":"55","author":"Peng","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: An Emerging Global Opportunistic Pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1086\/600042","article-title":"Infection with panresistant Klebsiella pneumoniae: A report of 2 cases and a brief review of the literature","volume":"49","author":"Elemam","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2008.05.016","article-title":"Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients","volume":"32","author":"Falagas","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","first-page":"3","article-title":"Tackling Threats and Future Problems of Multidrug-Resistant Bacteria","volume":"398","author":"Medina","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"fnw084","DOI":"10.1093\/femsle\/fnw084","article-title":"Keeping it simple: Lessons from the golden era of antibiotic discovery","volume":"363","author":"Lyddiard","year":"2016","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1056\/NEJMp1402114","article-title":"Drug development and FDA approval, 1938\u20132013","volume":"370","author":"Darrow","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","first-page":"1107","article-title":"Round table: Are new antibiotics needed?","volume":"5","author":"Finland","year":"1965","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijantimicag.2003.11.003","article-title":"Oxazolidinones: Activity, mode of action, and mechanism of resistance","volume":"23","author":"Bozdogan","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2012.07.010","article-title":"Pharmacokinetics and pharmacodynamics of \u201cold\u201d polymyxins: What is new?","volume":"74","author":"Bergen","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0972-5229.56048","article-title":"Colistin and polymyxin B: A re-emergence","volume":"13","author":"Gupta","year":"2009","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","article-title":"Colistin in the 21st Century","volume":"22","author":"Nation","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciy659","article-title":"In Vitro Activities of Ceftaroline\/Avibactam, Ceftazidime\/Avibactam, and Other Comparators against Pathogens from Various Complicated Infections in China","volume":"67","author":"Zhou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17425255.2019.1563071","article-title":"Novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: Expectations for the treatment of carbapenem-resistant Gram-negative pathogens","volume":"15","author":"Karaiskos","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/cc13948","article-title":"The future of antibiotics","volume":"18","author":"Spellberg","year":"2014","journal-title":"Crit. Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1086\/591411","article-title":"Infectious Diseases Society of America Position paper: Recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia","volume":"47","author":"Spellberg","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd3975","article-title":"Platforms for antibiotic discovery","volume":"12","author":"Lewis","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","article-title":"Why is big Pharma getting out of antibacterial drug discovery?","volume":"6","author":"Projan","year":"2003","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1465-0691.2004.1008.x","article-title":"Antibacterial drug discovery: Is small pharma the solution?","volume":"10","author":"Boggs","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrmicro3245","article-title":"ND4BB: Addressing the antimicrobial resistance crisis","volume":"12","author":"Rex","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Infectious Diseases Society of America (2010). The 10 \u00d7 \u201920 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis., 50, 1081\u20131083.","DOI":"10.1086\/652237"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/03009734.2014.896437","article-title":"Discovery and preclinical development of new antibiotics","volume":"119","author":"Hughes","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bcp.2016.11.002","article-title":"New approaches to antimicrobial discovery","volume":"134","author":"Lewis","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10529-017-2311-8","article-title":"New approaches to antibiotic discovery","volume":"39","author":"Kealey","year":"2017","journal-title":"Biotechnol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfn121","article-title":"Caenorhabditis elegans: An Emerging Model in Biomedical and Environmental Toxicology","volume":"106","author":"Leung","year":"2008","journal-title":"Toxicol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-60327-545-3_5","article-title":"Whole-animal high-throughput screens: The C. elegans model","volume":"486","author":"Conery","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-0028-1129486","article-title":"Ein Beitrag zur Chemotherapie der bakteriellen Infektionen","volume":"61","author":"Domagk","year":"1935","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Kudelski","year":"1975","journal-title":"J. Antibiot."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/jb.40.4.581-600.1940","article-title":"The Soil as a Source of Microorganisms Antagonistic to Disease-Producing Bacteria","volume":"40","author":"Waksman","year":"1940","journal-title":"J. Bacteriol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt784","article-title":"A genomics-guided approach for discovering and expressing cryptic metabolic pathways","volume":"21","author":"Zazopoulos","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1128\/AEM.01754-09","article-title":"Use of Ichip for High-Throughput In Situ Cultivation of \u201cUncultivable\u201d Microbial Species","volume":"76","author":"Nichols","year":"2010","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Shannon, E., and Abu-Ghannam, N. (2016). Antibacterial Derivatives of Marine Algae: An Overview of Pharmacological Mechanisms and Applications. Mar. Drugs, 14.","DOI":"10.3390\/md14040081"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/nbt1206-1504","article-title":"Prospects for plant-derived antibacterials","volume":"24","author":"Lewis","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1073\/pnas.1000087107","article-title":"Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation","volume":"108","author":"Dethlefsen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: Confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2174\/0929867324666170815102441","article-title":"Antimicrobial Peptides: A Promising Therapeutic Strategy in Tackling Antimicrobial Resistance","volume":"24","author":"Nuti","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nri1180","article-title":"Defensins: Antimicrobial peptides of innate immunity","volume":"3","author":"Ganz","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kumar, P., Kizhakkedathu, J.N., and Straus, S.K. (2018). Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules, 8.","DOI":"10.3390\/biom8010004"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"18040","DOI":"10.3390\/ijms151018040","article-title":"Novel Formulations for Antimicrobial Peptides","volume":"15","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three Decades of \u03b2-Lactamase Inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Spengler, G., Kincses, A., Gajdacs, M., and Amaral, L. (2017). New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules, 22.","DOI":"10.3390\/molecules22030468"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.45.1.105-116.2001","article-title":"Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy","volume":"45","author":"Lomovskaya","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Stadler, M., and Dersch, P. (2016). Anti-virulence Strategies to Target Bacterial Infections. How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives, Springer International Publishing. Current Topics in Microbiology and Immunology.","DOI":"10.1007\/978-3-319-49284-1"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrmicro1818","article-title":"The biology and future prospects of antivirulence therapies","volume":"6","author":"Cegelski","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.micpath.2018.05.046","article-title":"Developments in strategies for Quorum Sensing virulence factor inhibition to combat bacterial drug resistance","volume":"121","author":"Haque","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with Monoclonal Antibodies against Clostridium difficile Toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Love, M.J., Bhandari, D., Dobson, R.C.J., and Billington, C. (2018). Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care. Antibiotics (Basel), 7.","DOI":"10.3390\/antibiotics7010017"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fmb.12.97","article-title":"Bacteriophage endolysins as novel antimicrobials","volume":"7","author":"Schmelcher","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e01379-14","DOI":"10.1128\/mBio.01379-14","article-title":"Engineered Endolysin-Based \u201cArtilysins\u201d To Combat Multidrug-Resistant Gram-Negative Pathogens","volume":"5","author":"Briers","year":"2014","journal-title":"mBio"},{"key":"ref_73","first-page":"1","article-title":"Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies","volume":"31","author":"Kashani","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2017.01.003","article-title":"What is an \u201cideal\u201d antibiotic? Discovery challenges and path forward","volume":"133","author":"Singh","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram-Positive Bacterial Infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dku379","article-title":"Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: Systematic review and meta-analysis","volume":"70","author":"Nemeth","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the Myth of \u201cStatic vs Cidal\u201d: A Systemic Literature Review","volume":"66","author":"Holtom","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Redelinghuys, M.J., Ehlers, M.M., Dreyer, A.W., Lombaard, H.A., and Kock, M.M. (2014). Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in pregnant women. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-171"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Briers, Y., Staubli, T., Schmid, M.C., Wagner, M., Schuppler, M., and Loessner, M.J. (2012). Intracellular Vesicles as Reproduction Elements in Cell Wall-Deficient L-Form Bacteria. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038514"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"120143","DOI":"10.1098\/rsob.120143","article-title":"L-form bacteria, cell walls and the origins of life","volume":"3","author":"Errington","year":"2013","journal-title":"Open Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20150494","DOI":"10.1098\/rstb.2015.0494","article-title":"L-form bacteria, chronic diseases and the origins of life","volume":"371","author":"Errington","year":"2016","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1128\/AEM.02636-13","article-title":"Bacterial Persister Cell Formation and Dormancy","volume":"79","author":"Wood","year":"2013","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/femsre\/fux001","article-title":"Formation, physiology, ecology, evolution and clinical importance of bacterial persisters","volume":"41","author":"Fauvart","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","article-title":"Persistent bacterial infections and persister cells","volume":"15","author":"Fisher","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijos.2014.65","article-title":"Strategies for combating bacterial biofilm infections","volume":"7","author":"Wu","year":"2015","journal-title":"Int. J. Oral Sci."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Limoli, D.H., Jones, C.J., and Wozniak, D.J. (2015). Bacterial Extracellular Polysaccharides in Biofilm Formation and Function. Microbiol. Spectr., 3.","DOI":"10.1128\/microbiolspec.MB-0011-2014"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0966-842X(00)01918-1","article-title":"Cystic fibrosis pathogenesis and the role of biofilms in persistent infection","volume":"9","author":"Costerton","year":"2001","journal-title":"Trends Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/jac\/dkx192","article-title":"Evaluation of combinations of putative anti-biofilm agents and antibiotics to eradicate biofilms of Staphylococcus aureus and Pseudomonas aeruginosa","volume":"72","author":"Belfield","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/2049-632X.12141","article-title":"Anti-biofilm agents: Recent breakthrough against multi-drug resistant Staphylococcus aureus","volume":"70","author":"Chung","year":"2014","journal-title":"Pathog. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acsinfecdis.5b00097","article-title":"Permeability Barrier of Gram-Negative Cell Envelopes and Approaches to Bypass It","volume":"1","author":"Zgurskaya","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/17460441.3.5.487","article-title":"Are natural products still the best source for antibacterial discovery? The bacterial entry factor","volume":"3","author":"Silver","year":"2008","journal-title":"Expert Opin. Drug. Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1021\/jm700967e","article-title":"Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery","volume":"51","author":"Moser","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e01541-16","DOI":"10.1128\/mBio.01541-16","article-title":"Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules","volume":"7","author":"Miller","year":"2016","journal-title":"mBio"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17460441.2018.1455660","article-title":"Overcoming problems of poor drug penetration into bacteria: Challenges and strategies for medicinal chemists","volume":"13","author":"Tiz","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CMR.00043-12","article-title":"Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance","volume":"25","author":"Hancock","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbapap.2008.11.005","article-title":"Outer Membrane Permeability and Antibiotic Resistance","volume":"1794","author":"Delcour","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/dkg050","article-title":"The importance of efflux pumps in bacterial antibiotic resistance","volume":"51","author":"Webber","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fphar.2013.00168","article-title":"Efflux pumps of Gram-negative bacteria: What they do, how they do it, with what and how to deal with them","volume":"4","author":"Amaral","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2174\/138161211795703726","article-title":"Microbial Efflux Pump Inhibition: Tactics and Strategies","volume":"17","author":"Tegos","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Hefti, F.F. (2008). Requirements for a lead compound to become a clinical candidate. BMC Neurosci., 9.","DOI":"10.1186\/1471-2202-9-S3-S7"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/clinids\/24.3.457","article-title":"Oral administration of antibiotics: A rational alternative to the parenteral route","volume":"24","author":"MacGregor","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Li, H.K., Agweyu, A., English, M., and Bejon, P. (2015). An unsupported preference for intravenous antibiotics. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001825"},{"key":"ref_104","unstructured":"Brunton, L., Chabner, B.A., and Knollman, B. (2011). Goodman & Gillman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill. [12th ed.]."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_107","first-page":"67","article-title":"[Prediction of ADME properties for selenocompounds with anticancer and efflux pump inhibitory activity using preliminary computational methods] (article in Hungarian)","volume":"88","author":"Handzlik","year":"2018","journal-title":"Acta Pharm. Hung."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp0600182","article-title":"A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan","volume":"3","author":"Takagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000094668","article-title":"Principles of antibiotic penetration into abscess fluid","volume":"78","author":"Wagner","year":"2006","journal-title":"Pharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn","year":"2003","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_112","first-page":"218","article-title":"Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives","volume":"9","author":"Lemaire","year":"2006","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrmicro.2017.59","article-title":"Engineering of obligate intracellular bacteria: Progress, challenges and paradigms","volume":"15","author":"McClure","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: Design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/34.3.371","article-title":"Azithromycin uptake and intracellular accumulation by Toxoplasma gondii-infected macrophages","volume":"34","author":"Blais","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.49.6.2372-2377.2005","article-title":"Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin","volume":"49","author":"Bosnar","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00404-010-1646-3","article-title":"Antibiotic chemotherapy during pregnancy and lactation period: Aspects for consideration","volume":"283","author":"Mylonas","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","article-title":"Antibiotic use in pregnancy and lactation: What is and is not known about teratogenic and toxic risks","volume":"107","author":"Nahum","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jpeds.2016.11.027","article-title":"Antibiotic Use in Children\u2014A Cross-National Analysis of 6 Countries","volume":"182","author":"Youngster","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.2017.16477","article-title":"Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS","volume":"319","author":"Kim","year":"2018","journal-title":"JAMA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: A Review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/156802611794480882","article-title":"Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development","volume":"11","author":"Nettleton","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/428839","article-title":"Nitazoxanide: A New Thiazolide Antiparasitic Agent","volume":"40","author":"Fox","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"Edlund","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000481224","article-title":"Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori","volume":"93","author":"Adachi","year":"2017","journal-title":"Oncology"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Butenko, T., Jeverica, S., Orel, R., and Homan, M. (2017). Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. Helicobacter, 22.","DOI":"10.1111\/hel.12400"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4251\/wjgo.v7.i12.455","article-title":"Helicobacter pylori in gastric carcinogenesis","volume":"7","author":"Ahn","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jac\/dki443","article-title":"Molecular investigation of genetic elements contributing to metronidazole resistance in Bacteroides strains","volume":"57","author":"Gal","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., Spengler, G., and Urb\u00e1n, E. (2017). Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik\u2019s Cube of Clinical Microbiology?. Antibiotics (Basel), 6.","DOI":"10.3390\/antibiotics6040025"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anaerobe.2017.04.007","article-title":"Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015","volume":"47","author":"Jeverica","year":"2017","journal-title":"Anaerobe"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(62)92243-2","article-title":"Metronidazole in acute ulcerative gingivitis","volume":"279","author":"Shinn","year":"1962","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"a017822","DOI":"10.1101\/cshperspect.a017822","article-title":"Tuberculosis Treatment and Drug Regimens","volume":"5","author":"Sotgiu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.chom.2008.05.006","article-title":"Mycobacterium tuberculosis and the Macrophage: Maintaining a Balance","volume":"3","author":"Pieters","year":"2008","journal-title":"Cell Host Microbe"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Shi, W., Zhang, W., and Mitchison, D. (2014). Mechanisms of Pyrazinamide Action and Resistance. Microbiol. Spectr., 2.","DOI":"10.1128\/microbiolspec.MGM2-0023-2013"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20062100","article-title":"Mechanism of thioamide drug action against tuberculosis and leprosy","volume":"204","author":"Wang","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"ref_140","unstructured":"(2019, January 23). The Selection and Use of Essential Medicines. Available online: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML_2017_ExecutiveSummary.pdf?ua=1."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jac\/dkr173","article-title":"Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and new drugs","volume":"66","author":"Palomino","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Witek, K., Nasim, M.J., Bischoff, M., Gaupp, R., Arsenyan, P., Vasiljeva, J., Mar\u0107, M.A., Olejarz, A., Latacz, G., and Kie\u0107-Kononowicz, K. (2017). Selenazolinium Salts as \u201cSmall Molecule Catalysts\u201d with High Potency against ESKAPE Bacterial Pathogens. Molecules, 22.","DOI":"10.3390\/molecules22122174"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tim.2016.12.008","article-title":"The Role of Reactive Oxygen Species in Antibiotic-Mediated Killing of Bacteria","volume":"25","author":"Acker","year":"2017","journal-title":"Trends Microbiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e00141-11","DOI":"10.1128\/mBio.00141-11","article-title":"Antimicrobial Actions of Reactive Oxygen Species","volume":"2","author":"Fang","year":"2011","journal-title":"mBio"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.1232688","article-title":"Killing by Bactericidal Antibiotics Does Not Depend on Reactive Oxygen Species","volume":"339","author":"Keren","year":"2013","journal-title":"Science"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.1232751","article-title":"Cell Death from Antibiotics without the Involvement of Reactive Oxygen Species","volume":"339","author":"Liu","year":"2013","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic Adjuvants: Rescuing Antibiotics from Resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Ha, D.R., Haste, N.M., and Gluckstein, D.P. (2017). The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use. Am. J. Lifestyle Med.","DOI":"10.1177\/1559827617700824"},{"key":"ref_149","first-page":"26","article-title":"[The attitude of community pharmacists towards their widening roles in the prevention and treatment of infectious diseases in the southeast region of Hungary] (article in Hungarian)","volume":"63","author":"Paulik","year":"2019","journal-title":"Gy\u00f3gyszer\u00e9szet"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Infectious Diseases Society of America (2011). An unmet medical need: Rapid molecular diagnostics tests for respiratory tract infections. Clin. Infect. Dis., 52, S384\u2013S395.","DOI":"10.1093\/cid\/cir055"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/5\/892\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:35:59Z","timestamp":1760186159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/5\/892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,3]]},"references-count":150,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["molecules24050892"],"URL":"https:\/\/doi.org\/10.3390\/molecules24050892","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,3]]}}}